je.st
news
Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity
2014-05-06 14:59:00| Merck.com - Corporate News
Dateline City: BOSTON Company Provides Updates on Near-Term Opportunities and Immuno-Oncology Strategy Announced Sale of Consumer Care Business to Bayer AG for $14.2 Billion; Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease MK-3475 BLA Accepted for Priority Review by FDA; Company Announced Plans to File in EU in 2014 Provided Updates on Clinical Development Programs for Oncology, Hepatitis C and HIV Confirmed Plans to File Odanacatib for the Treatment of Osteoporosis in Second Half of 2014 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today is hosting an Investor Briefing at the companys research facility in Boston. The briefing is also available via webcast at www.merck.com starting at 9:00 a.m. EDT. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Ian McConnell 908-423-3046Investor:Joe Romanelli, 908-423-5185Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: drive
commercial
focus
growth
Category:Biotechnology and Pharmaceuticals